Dataset Information

Targeting protein-protein interactions for therapeutic discovery via FRET-based high-throughput screening in living cells.

ABSTRACT: We have developed a structure-based high-throughput screening (HTS) method, using time-resolved fluorescence resonance energy transfer (TR-FRET) that is sensitive to protein-protein interactions in living cells. The membrane protein complex between the cardiac sarcoplasmic reticulum Ca-ATPase (SERCA2a) and phospholamban (PLB), its Ca-dependent regulator, is a validated therapeutic target for reversing cardiac contractile dysfunction caused by aberrant calcium handling. However, efforts to develop compounds with SERCA2a-PLB specificity have yet to yield an effective drug. We co-expressed GFP-SERCA2a (donor) in the endoplasmic reticulum membrane of HEK293 cells with RFP-PLB (acceptor), and measured FRET using a fluorescence lifetime microplate reader. We screened a small-molecule library and identified 21 compounds (Hits) that changed FRET by >3SD. 10 of these Hits reproducibly alter SERCA2a-PLB structure and function. One compound increases SERCA2a calcium affinity in cardiac membranes but not in skeletal, suggesting that the compound is acting specifically on the SERCA2a-PLB complex, as needed for a drug to mitigate deficient calcium transport in heart failure. The excellent assay quality and correlation between structural and functional assays validate this method for large-scale HTS campaigns. This approach offers a powerful pathway to drug discovery for a wide range of protein-protein interaction targets that were previously considered "undruggable".

SUBMITTER: Stroik DR

PROVIDER: S-EPMC6105598 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Targeting protein-protein interactions for therapeutic discovery via FRET-based high-throughput screening in living cells.

Stroik Daniel R DR Yuen Samantha L SL Janicek Kevyn A KA Schaaf Tory M TM Li Ji J Ceholski Delaine K DK Hajjar Roger J RJ Cornea Razvan L RL Thomas David D DD

Scientific reports 20180822 1

We have developed a structure-based high-throughput screening (HTS) method, using time-resolved fluorescence resonance energy transfer (TR-FRET) that is sensitive to protein-protein interactions in living cells. The membrane protein complex between the cardiac sarcoplasmic reticulum Ca-ATPase (SERCA2a) and phospholamban (PLB), its Ca-dependent regulator, is a validated therapeutic target for reversing cardiac contractile dysfunction caused by aberrant calcium handling. However, efforts to develo ...[more]

PMID: 30135432

Similar Datasets

Project description:PPAR? is a pharmacological target in inflammatory and metabolic diseases. Upon agonistic treatment or following antagonism, binding of co-factors is altered, which consequently affects PPAR?-dependent transactivation as well as its DNA-independent properties. Therefore, establishing techniques to characterize these interactions is an important issue in living cells. Methods: Using the FRET pair Clover/mRuby2, we set up a flow cytometry-based FRET assay by analyzing PPAR?1 binding to its heterodimerization partner RXR?. Analyses of PPAR?-reporter and co-localization studies by laser-scanning microscopy validated this system. Refining the system, we created a new readout to distinguish strong from weak interactions, focusing on PPAR?-binding to the co-repressor N-CoR2. Results: We observed high FRET in cells expressing Clover-PPAR?1 and mRuby2-RXR?, but no FRET when cells express a mRuby2-RXR? deletion mutant, lacking the PPAR? interaction domain. Focusing on the co-repressor N-CoR2, we identified in HEK293T cells the new splice variant N-CoR2-?ID1-exon. Overexpressing this isoform tagged with mRuby2, revealed no binding to Clover-PPAR?1, nor in murine J774A.1 macrophages. In HEK293T cells, binding was even lower in comparison to N-CoR2 constructs in which domains established to mediate interaction with PPAR? binding are deleted. These data suggest a possible role of N-CoR2-?ID1-exon as a dominant negative variant. Because binding to N-CoR2-mRuby2 was not altered following activation or antagonism of Clover-PPAR?1, we determined the effect of pharmacological treatment on FRET intensity. Therefore, we calculated flow cytometry-based FRET efficiencies based on our flow cytometry data. As with PPAR? antagonism, PPAR? agonist treatment did not prevent binding of N-CoR2. Conclusion: Our system allows the close determination of protein-protein interactions with a special focus on binding intensity, allowing this system to characterize the role of protein domains as well as the effect of pharmacological agents on protein-protein interactions.

Dataset Information

Targeting protein-protein interactions for therapeutic discovery via FRET-based high-throughput screening in living cells.

Publications

Targeting protein-protein interactions for therapeutic discovery via FRET-based high-throughput screening in living cells.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets